THE WIRE · № 61244
Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs
01 THE MACHINE READ
WHY IT MATTERS.
Novartis licensing Abogen's mRNA T-cell engager validates RNA platform value, but Abogen is private so listed peers see only sentiment spillover.
Private deal, limited direct listed-market impact
Further Novartis option exercises or trial starts
Deal terms undisclosed, no revenue visibility
FULL DISPATCH
Includes worldwide license to ABO2203, Abogen's mRNA-encoded CD19xCD3 T-Cell Engager Agreement also gives Novartis exclusive options to license other potential programs leveraging Abogen's RNA proprietary platform SUZHOU, China, Oct. 2, 2026 /PRNewswire/ -- Abogen Biosciences ("Abogen" or...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
2 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
Brazil votes in high-stakes election as U.S.-China rivalry and debt loom large2026-10-02 05:00 UTC
Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes2026-09-30 14:15 UTC
Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.2026-09-30 14:32 UTC
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial2026-09-30 14:32 UTC
Chinese refiners suspend October fuel exports to bolster stocks, sources say2026-10-01 04:57 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.